Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 31 March 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
As あゆみ製薬ホールディングス and its subsidiaries became consolidated subsidiaries on 1 July 2026, their revenue has been incorporated into the consolidated forecast from the second half of the fiscal year (third quarter). Profit items have been left undisclosed because the feasibility, timing and scale of upfront investments related to F351, as well as research and development expenses related to clinical trials in the United States and elsewhere, remain undetermined, making it impossible to accurately estimate the costs.
| Item | Details |
|---|---|
| Net Sales | ¥27,158 million → ¥47,327 million（74.3%） |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 31 March 2026 |
| Previous-period results | Revenue ¥26,840 million / Operating profit -¥3,471 million / Income before taxes -¥4,634 million / Profit for the period -¥7,150 million / Profit for the period attributable to owners of the parent -¥4,244 million / Basic earnings per share -¥80.90 |
| Reason for the revision | As あゆみ製薬ホールディングス and its subsidiaries became consolidated subsidiaries on 1 July 2026, their revenue has been incorporated into the consolidated forecast from the second half of the fiscal year (third quarter). Profit items have been left undisclosed because the feasibility, timing and scale of upfront investments related to F351, as well as research and development expenses related to clinical trials in the United States and elsewhere, remain undetermined, making it impossible to accurately estimate the costs. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As the acquisition of all shares in あゆみ製薬ホールディングス was completed on 1 July 2026 and the company and its subsidiaries became consolidated subsidiaries, their revenue has been incorporated into the consolidated forecast from the second half of the fiscal year ending December 2026. Operating profit, profit before tax and profit for the period attributable to owners of the parent have been left undisclosed because upfront investments toward the approval and launch of F351 and research and development expenses related to clinical trials in the United States remain undetermined, making it difficult to reasonably estimate their impact.